Leukotriene antagonists

Novateur Ventures explores new strategy to reduce the hyperinflammatory response caused by COVID-19

Retrieved on: 
Thursday, August 6, 2020

VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.
  • The study titled A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes was published in Frontiers in Pharmacology , a leading peer-reviewed journal.
  • The strategy co-authored by Ali Ardakani, Founder & Managing Director at Novateur Ventures, and Dr. Colin D. Funk (Queen's University, Kingston) analyzes lipid mediators, known as leukotrienes, as the cause for hyperinflammatory response manifested in severe COVID-19 cases.
  • The proposed zileuton/montelukast combination could readily be added in this setting, with the goal to switch off the hyper-inflammatory response.